Argenx Shares Plunge On Clinical Trial's Halt -- WSJ
The company separately said it would move to late-stage development of a celiac-disease drug it acquired this year By Adrià Calatayud Argenx shares fell sharply after the biotech company stopped a late-stage clinical trial of its Vyvgart drug due to lack of efficacy for the treatment of autoimmune condition Sjogren's d